RANCHO CORDOVA, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today it has signed a distribution agreement covering China and Hong Kong for its products used to prepare cell concentrates, including stem cells, from bone marrow, at the point-of-care and in the laboratory.
The four-year agreement is with Nanshan Memorial Medical Institute (Nanshan), a progressive regenerative medicine company in China and Hong Kong that distributes medical products and has operated multiple, large healthcare facilities, including hospitals, stem cell banks and research centers. Under the agreement, Nanshan will have exclusive distribution rights for the Company's Res-Q™ 60 BMC (Res-Q) System and the MXP™ MarrowXpress products.
Dr. Lu Daopei is founder and serves as medical director on behalf of Nanshan. Dr. Lu is a world-renowned hematologist and expert in the field of hematopoietic stem cell transplants. He pioneered the first successful syngeneic bone marrow stem cell transplant in the People's Republic of China to treat aplastic anemia and the first allogeneic peripheral blood stem cell transplant to treat acute leukemia.
"This agreement represents a major milestone in our strategy to expand the geographic reach of our offerings into a very exciting market opportunity for the Company," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis. "We believe Dr. Lu's reputation as a pioneer in hematological medicine and leading stem cell expert in China, combined with the strong, in-country presence of Nanshan, will greatly enhance ThermoGenesis' ability to achieve timely government approvals and market adoption of our bone marrow technologies," he added.
During phase one of the distribution agreeme